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400Objective: Long-term evolution of polycaprolactone vascular prostheses has been investigated recently. The
goal of this study was to evidence a noninferiority of such grafts compared with expanded polytetrafluoroethy-
lene (ePTFE) implants in an aortic replacement model in the rat.
Methods: Fourteen anesthetized Sprague-Dawley rats received an infrarenal aortic graft (biodegradable, n¼ 8;
expanded polytetrafluoroethylene, n¼ 6) replacement (end to end; inner diameter, 2 mm). Biodegradable grafts
(polycaprolactone) were produced by randommicro-/nanofiber electrospinning. After a median survival of 16.5
months, in vivo ultrasonography and angiography as well as postexplantation microcomputed tomography,
histomorphometry, immunohistochemistry, and scanning electron microscopy were performed.
Results: Patency was 100% for polycaprolactone and 67% for ePTFE. No aneurysmal dilatation or stenoses
were found in either group. Compliance was significantly higher for polycaprolactone compared with ePTFE
(8.2  1.0%/100 mm Hg vs 5.7  0.7%/100 mm Hg; P<.01), but markedly reduced compared with adjacent
native aortas and the control group. Histologically, low cellular in-growth was found in ePTFE whereas poly-
caprolactone showed significantly greater homogenous cellularity, producing an autologous extracellular matrix
(10.8%  4.0% vs 32.1%  9.2%, P<.0001). Morphometry showed 100% neo-endothelialization for both
grafts with a totally confluent endothelial coverage for polycaprolactone grafts by scanning electron microscope.
More intimal hyperplasia was found in ePTFE compared with polycaprolactone grafts. Calcification was higher
in ePTFE than in polycaprolactone grafts (15.8% vs 7.0%, P ¼ .04) and was absent in controls.
Conclusions:Outcomes of synthetic biodegradable nanofiber polycaprolactone grafts are not inferior compared
with the clinically used expanded polytetrafluoroethylene grafts after long-term implantation in the rat aorta.
Moreover, these implants show better patency, compliance, endothelialization, and cell in-growth, and less in-
timal hyperplasia and calcification than their counterparts. (J Thorac Cardiovasc Surg 2013;146:400-7)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular Surgbest clinical outcome compared with currently available
vascular prostheses.1 Biologically stable synthetic grafts
such as expanded polytetrafluoroethylene (ePTFE) and
polyethylene terephthalate (Dacron) grafts are used suc-
cessfully for the replacement of large-diameter vessels,
but are prone to thrombosis and intimal hyperplasia
development when used as small-diameter vessel replace-
ments (<6 mm).2 Because autologous vascular material is
not always available or appropriate, it would be greatly ben-
eficial to have a shelf-ready alternative. A significant
research effort has been led in this direction for the past
20 years, but no real solutions have emerged.3
Our in vivo tissue engineering approach to resolve the
problem of small-diameter vascular grafts is based on the
use of a synthetic, biodegradable, electrospun, nanoscaffold
to serve as a guide for the regeneration of a new vessel with
autologous cells and extracellular matrix (ECM). The use of
a biodegradable material avoids problems linked to long-
term residency of synthetic materials in arterial circulation,
such as foreign body reaction and infections.4 Other ap-
proaches to small-diameter vascular prostheses have also
been explored,5 such as biodegradable scaffolds with pre-
implantation cell seeding with6,7 or without8 bioreactor
maturation, or cell sheet-based tissue engineered grafts.9ery c August 2013
Abbreviations and Acronyms
ECM ¼ extracellular matrix
ePTFE ¼ expanded polytetrafluoroethylene
PCL ¼ polycaprolactone
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which is not the case for the these cell-based grafts.
In this study, the long-term results of a biodegradable
synthetic vascular graft were evaluated and compared
with the commercially available ePTFE graft as an aortic
replacement in the rat model. The evaluated graft was a mi-
cro- and nanofiber-based 2-mm-inner diameter vascular
prosthesis made from randomly oriented electrospun poly-
caprolactone (PCL) fibers. Its highly porous structure
makes it suitable for cell infiltration and allows uniform
degradation throughout the graft while natural tissues re-
generate. In previous studies carried out by our group, this
graft was characterized and evaluated in detail, both
in vitro and in vivo, in the rat abdominal aorta replacement
model for up to 6 months.10,11 In a recent publication by our
group, we demonstrated the long-term evolution of PCL
grafts (18 months).12 They showed very promising results,
with rapid endothelialization, limited neointima formation,
and graft patency throughout the entire follow-up period.
However, despite this good performance, PCL has some
well-established limitations in the long term (eg, calcifica-
tion, changes in cellular density).12 Little is known whether
these drawbacks are comparable with problems encoun-
tered during long-term implantation of ePTFE grafts, which
are commonly used clinically.
The objective of our study was to prove the noninferiority
of biodegradable PCL grafts compared with stable ePTFE
implants of the same caliber in a rat model during a period
up to 18 months. To achieve our goal, both grafts were com-
pared with regard to patency, aneurysmal dilation, cell inva-
sion, endothelialization, intimal hyperplasia, compliance,
and calcification.METHODS
The experimental protocol was approved by the Animal Experiments
Ethical Committee of the University of Geneva (Protocol:06/52) and the
Veterinary Office of the State of Geneva, Switzerland (1081/3232/II),
and carried out in conformity with the Guide for Care and Use of Labora-
tory Animals.13
Preparation of Vascular Grafts
The 2-mm-inner diameter biodegradable vascular grafts made
from PCL were obtained by electrospinning a solution of 15% w:v PCL
(Mw ¼ 80,000 g/mol; Sigma, Hamburg, Germany) and CHCl3/EtOH
(7:3, v:v) (Reidel-de-Ha€en, Seelze, Germany; H€anseler, Herisau, Switzer-
land) as described previously in detail.10,11 In brief, the solution is ejected
from a charged needle (20 kV) at a flow rate of 12mL/hour. The presence of
the high electrical field creates micro- and nanopolymer fibers, which are
collected onto a 2-mm-diameter groundedmandrel 20 cm from the ejectingThe Journal of Thoracic and Caneedle, which is both rotating and translating to ensure a homogenous ran-
dom deposition of the fibers. All grafts had a mean fiber diameter of 2.2 
0.6 mm, a maximum tensile stress of 4.1 0.5MPa, and a maximum tensile
strain of 1092 28% after sterilization by g-radiation (25 kGy). Commer-
cially available ePTFE grafts served as controls (30-mm thru-pore, 2-mm
inner diameter; Atrium, Mijdrecht, The Netherlands).
Implantation
Eight PCL grafts and 6 ePTFE grafts were implanted in 14 male
Sprague-Dawley rats (275 g) under 2% isoflurane mask anesthesia after in-
duction by 5% isoflurane. The rat abdomen was opened with a midline lap-
arotomy incision, and the infrarenal abdominal aorta was isolated by blunt
and sharp dissection. After proximal and distal clamping below the renal
arteries and above the aortoiliac bifurcation, a 1-cm segment of the aorta
was resected in a beveled way. Polycaprolactone or ePTFE grafts
(20 mm long) were implanted with 10-0 nylon interrupted sutures using
an operative microscope at 10 times magnification under sterile conditions.
Surgical handling and suture retention were better than ePTFE grafts, and
hemostasis of PCL grafts was excellent after declamping the aorta.
Patency, Stenosis, and Aneurysmal Dilatation
At the end of the follow-up period, the following studies were per-
formed after the animals were sacrificed: in vivo noninvasive compliance
measurements of the graft and the aorta as well as digital subtraction angi-
ography (General Electric Cardiac Series, 9800; Salt Lake City, Utah). The
animals were sacrificed with a pentobarbital overdose, and the infrarenal
proximal and distal segment of the abdominal aorta, including the graft,
was explanted. Six sex- and age-matched rats, which served as controls, un-
derwent the same examinations.
In Vivo Compliance
Compliance is a measure of the elastic deformation of a material in re-
sponse to pressure. According to the American National Standards Institute
guidelines,14 it is calculated as follows:
% Compliance=100 mm Hg ¼

Rp2Rp1

Rp1
p2p1 310
4;
where p1 is the lower pressure value, p2 is the higher pressure value (mea-
sured in millimeters of mercury), and Rp1 and Rp2 are the vessel inner di-
ameters at the respective pressures. Compliance of the implanted grafts
and the adjacent native aorta were measured in vivo in all rats before graft
explantation. Rats were kept under narcosis with a 2% isoflurane mask
while high-resolution ultrasound imaging (Vevo 770; Visualsonics,
Toronto, Ontario, Canada) was performed. One hundred frame videos at
a 71-Hz frame rate were recorded at standard locations (mid graft, and
proximal and distal native aorta). The rats’ blood pressure was measured
simultaneously with a noninvasive tail cuff system (CODA; Kent Scientific
Corporation, Torrington, Conn). Using standard image processing software
(ImageJ, ver. 1.44k, 2010; National Institutes of Health, Bethesda, Md),
vessel diameters were measured on each frame. Average systolic and dia-
stolic diameters were calculated from approximately 10 heart cycles. These
data were then used to calculate the compliance according to the previous
formula.Histology and Morphologic Quantitative Analysis
For the histologic evaluation, explanted grafts with both anastomoses
were fixed in 4% formaldehyde for 24 hours and embedded in paraffin.
Longitudinal, 4-mm thick histologic sections were stained with hematoxy-
lin–eosin, Miller-Masson for elastin and collagen staining, and von Kossa
for calcium deposition. Immunohistochemistry was performed with anti-
CD34 antibody (sc-7045, dilution, 1:200; Santa Cruz Biotechnology, Inc,
Heidelberg, Germany) for endothelium and neo-angiogenesis staining,rdiovascular Surgery c Volume 146, Number 2 401
TABLE 1. Comparison between PCL and ePTFE grafts
Parameter PCL (n ¼ 8) ePTFE (n ¼ 6) P value
Survival, months  SD 14.8  2.9 16.0  3.1 .17
Patency,% 100 67 .46
Compliance,%/100 mm Hg
 SD
8.2  1.0 5.7  0.7 .01
Endothelialization,%  SD 100  0.0 99.6  1.0 .92
Neointima coverage,%  SD 67.9  17.1 77  15.6 .25
Average thickness of neointima,
mm;  SD
51.6  20.7 76.9  36.9 .09
Cellular in-growth,%  SD 32.1  9.2 10.8  4.0 <.001
Calcification,%  SD 7.0  5.0 15.8  3.2 .04
PCL, Polycaprolactone; ePTFE, expanded polytetrafluoroethylene; SD, standard
deviation.
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Schweiz Ag, Baar, Switzerland) for smooth muscle cells. Histologic slides
were scanned numerically in their totality at 10 times magnification (Mirax
scanner; Carl Zeiss MicroImaging GmbH, G€ottingen, Germany) for quan-
tifications with ImageJ (ImageJ, ver. 1.44k, 2010). The following measure-
ments were acquired from each slide: percent endothelial coverage
(percentage of the graft luminal surface covered by endothelial cells), neo-
intima coverage (percentage of the graft length covered with neointima),
average neointima thickness (the area between the endothelial layer and
the graft surface, normalized by the neointima length and measured in mi-
crometers), percent transmural cellular in-growth (percentage of the graft
area densely populated by host cells from the adventitial tissue toward
the luminal side).
In addition, scanning electron microscopy (Philips XL20 SEM, Eind-
hoven, The Netherlands) was used to scan longitudinal sections of ex-
planted grafts. Samples were prepared with standard dehydration and
gold coating techniques.
Evaluation of Calcification
Microcomputed tomographic ex vivo scans of the grafts and control aor-
tas were acquired at an 18-mm resolution on a Skyscan-1076 micro-CT
(Skyscan, Aartselaar, Belgium). Cross-sectional images were recon-
structed using a classic Feldkamp cone-beam algorithm.15 Calcium vol-
umes were extracted automatically based on densities superior to 200
Hounsfield units. Calcium percentages were calculated as the volume of
calcium divided by the total volume of the prosthesis/aorta.
Statistical Analysis
Results are expressed as a mean  standard deviation. Intergroup com-
parisons were performed with the use of Mann-Whitney U test. The Fisher
exact test was used for binary variables. Totally occluded grafts were ex-
cluded from the comparisons. A 2-tailed P value<.05 was considered sig-
nificant in all tests. P values between .05 and .1 marked a trend toward
statistical significance.RESULTS
Follow-up
The mean follow-up time was 14.8  2.9 months and
16.0  3.1 months in the PCL and ePTFE groups, respec-
tively (P ¼ .17; Table 1). One rat implanted with a PCL
graft developed severe breast tumors as a result of aging
and was sacrificed, although the graft was patent.Patency, Stenosis, and Aneurysmal Dilation
The PCL grafts had excellent patency rates (100%), but 2
of the ePTFE grafts were occluded at the conclusion of the
study, yielding a patency of 67% (P ¼ .46; Table 1 and
Figure 1, A). By angiographic assessment, no signs of
stenosis could be detected for the PCL grafts, and nonrele-
vant (<50% obstruction) stenoses were found for all patent
ePTFE grafts (Figure 1, B and C). Neither the PCL grafts
nor the ePTFE grafts showed signs of aneurysmal dilation.
Angiographies of the control aortas revealed 100% patency,
no stenosis, and no aneurysmal dilation (Figure 1, D).In Vivo Compliance
The diastolic and systolic inner diameters were calcu-
lated for the middle of the grafts and the adjacent proximal402 The Journal of Thoracic and Cardiovascular Surgand distal native aorta of both grafts (Figure E1).
The compliance of PCL implants was significantly greater
(P¼ .011) than ePTFE grafts: 8.2 1.0%/100 mmHg ver-
sus 5.7  0.7%/100 mm Hg, respectively. However, the
compliance of both PCL and ePTFE grafts was significantly
less than their adjacent native aortas and control nonoper-
ated aortas (Figure E2 and Table 1).
Morphologic Analysis of PCL Grafts
Polycaprolactone graftswere lined completelywith endo-
thelium, which was confirmed by CD34 immunohistochem-
istry (Figure 2, A and D), and populations of homogenously
distributed cells were present throughout the graft material
(Figure 2, B). In the graft bodies, numerous macrophages,
with a few myofibroblasts near the luminal side and neo-
angiogenesis could be found. The grafts were bordered by
a mild foreign body reaction, but there were no signs of
chronic inflammation. On the luminal side, spindle-shaped
cells beneath the endothelium formed a neointimal layer
(Figure 2, C). Focal calcium depositions were found at the
interface of the prosthesis and intimal hyperplasia, mainly
in proximity to the anastomoses, but seldom invading the
graft body (Figure 2, C). Miller-Masson staining shows
that new ECMwas produced by the cells in and on the lumi-
nal surface of the graft. Collagen deposition was found both
in the body of the graft (Figure 2, E), and elastin fibers were
found in the neointima (Figure 2, E). Smooth muscle cells
and myofibroblasts were labeled with anti-a smooth muscle
actin antibody and were found in the neointima layers, but
were scarce in the graft body (Figure 2, F).
Morphologic Analysis of the Expanded
Polytetrafluoroethylene Grafts
Histologic evaluation of the ePTFE grafts showed that
cell invasion was very limited and was comprised of only
a few lymphocytes, fibroblasts, and rare capillaries
(Figure 3, A). At the adventitial interface, no foreign body
reaction was found. Endothelial cells covered most of the
luminal surface, and neointimal layers under theery c August 2013
FIGURE 1. Evaluation of patency after 1-year implantation. (A) In vivo angiography before explantation reveals 1 obstructed ePTFE graft where irrigation
of the lower limbs is ensured by a collateral vessel. (B) In patent ePTFE grafts, flow is reduced, with signs of insignificant stenosis (<50%). (C) Patency of
PCL grafts was very good with no stenosis or aneurysmal dilation. (D) The patent native aorta of a control rat.
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trix deposition was limited to collagen on the inner side
of the graft in addition to collagen and elastin in the neoin-
tima layers (Figure 3, C). Several areas of calcium deposi-
tion were found only in the graft body and were never seen
in the neointima (Figure 3, D).
Scanning electron microscopic images show confluent
endothelialization of PCL grafts (Figure 2, A), but areas
of incomplete endothelial coverage were found on ePTFE
samples (Figure 3, E; insert). In addition, some areas of mi-
crothrombi were present on the luminal surface of 1 ePTFE
graft, and not on PCL grafts.Histologic Morphometric Analysis
Longitudinal histologic cross-sections revealed 100% en-
dothelialization in PCL and 99.6%  1.0% endothelializa-
tion in ePTFE grafts (Table 1). However, the minimal value
of endothelium coverage for ePTFE implants was 97%, con-
firming incompleteness of coverage in some grafts. The neo-
intimal coverage did not differ significantly in the studied
groups, and was 67.9%  17.1% and 77.0%  15.6% in
PCL and ePTFE implants, respectively (P ¼ .25). However,The Journal of Thoracic and Cathe average thickness of neointimawas less in the PCL group
(51.6 20.7 mm) than in the ePTFE group (76.9 36.9 mm;
Figure E3,A). This result shows a trend toward statistical sig-
nificance (P ¼ .09). Transmural cellular in-growth was sig-
nificantly greater (P< .001) in PCL prostheses (32.1% 
9.2%) than in the ePTFE counterparts (10.8%  4.0%;
Table 1 and Figure E3, B).Calcium Deposition
Calcifications of the PCL grafts were located at the inter-
face of the neointima–graft lumen (Figure 2, C) whereas in
ePTFE prostheses they were observed only in the body of
the implant (Figure 3, D). Calcium depositions were con-
firmed by microcomputed tomographic imaging of both
grafts (Figure 4), which revealed several areas of calcifica-
tion in all PCL and all ePTFE grafts, with the major ones of-
ten positioned near an anastomosis. Quantitative volumetric
assessment showed that calcification in ePTFE grafts was
significantly greater (P¼ .04) than in PCL grafts, with an av-
erage calcium content of 15.8%  3.2% compared with
7.0% 5.0% for thePCL-based grafts (Table 1).Native aor-
tas from the control animals had no detectable calcifications.rdiovascular Surgery c Volume 146, Number 2 403
FIGURE 2. Morphologic analysis of PLC grafts. (A) Scanning electron micrographic image of the lumen of the PCL graft after explantation showing
complete endothelialization. (B) Longitudinal section of the graft wall showing homogenous cellular infiltration giant cells on the periphery (arrows;
hematoxylin–eosin staining, 1003 magnification). (C) Neointima with spindle-shaped cells above a calcified area (arrow). An endothelium is present
on the luminal side (hematoxylin–eosin staining, 2003 magnification). (D) Immunohistochemistry anti-CD34 labeling endothelial cells on the luminal
side (2003 magnification). (E) Elastin deposition in the neointimal layers is revealed in blue and collagen deposition is revealed in green by Miller-
Masson staining (2003 magnification). (F) Immunohistochemistry anti-a smooth muscle actin demonstrating positivity in spindle-shaped cells forming
the neo-intima (2003 magnification).
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In the quest for a small-diameter vascular prosthesis, bio-
degradable synthetic grafts have become an important area
of research. In our study, we present results of 2-mm-inner
diameter PCL grafts implanted in the rat aorta for 12 to 18
months (thus, the average trial period of 14.8 months repre-
sents approximately 18 years in a human), and compare
them with ePTFE grafts and control native aortas. The per-
formance of PCL is equal to ePTFE in our study and even
better with regard to patency, compliance, intimal hyperpla-
sia, cellular in-growth, and calcification (Table 1).404 The Journal of Thoracic and Cardiovascular SurgAfter the follow-up period, all 8 PCL grafts evaluated
were patent and showed no signs of stenosis, whereas 2
ePTFE grafts out of 6 were thrombosed. Microthrombi
could also be spotted on the luminal surface of 1 patent
ePTFE graft by scanning electron microscopy. In a previous
report, we showed that endothelialization of our PCL grafts
occurs much more rapidly than on ePTFE grafts, and re-
mains stable and confluent for all further time points.11,12
Maintaining a stable antithrombotic surface is essential
for long-term success of a vascular prosthesis, and the
best surface is a functional endothelium.16 As seen in ourery c August 2013
FIGURE 3. Morphologic analysis of expanded polytetrafluoroethylene grafts. (A) Longitudinal section of the graft wall with neointima formation, limited
cellular infiltration in the graft body, and no giant cell reaction (hematoxylin–eosin staining, 1003 magnification). (B) Neointima formation under the en-
dothelium (arrow) with no signs of calcification (hematoxylin–eosin staining, 2003 magnification). (C) Miller-Masson staining revealing elastin fibers in
blue in the neointima and collagen depositions in green in the inner part of the graft (2003 magnification). (D) Von Kossa staining showing, in black, the
calcifications in the graft body (1003 magnification). (E) Scanning electron microscopic image of the lumen of the graft showing incomplete endotheli-
alization (insert) and microthrombi.
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pletely confluent; at 12 to 18months, some areas are lacking
an endothelium. This makes the ePTFE surface prone to
thrombosis and may explain the lesser patency rate and mi-
crothrombi observed in this study. Therefore, electrospun
PCL grafts show a better tendency toward long-term throm-
bus resistance.
As a biodegradable graft evolves over time toward a fully
regenerated vessel, the biomaterial degrades and the me-
chanical strength of the synthetic structure decreases. A de-
crease in molecular weight of approximately 80% was
found at 18 months after implantation.12 The ideal biomate-
rial should degrade in conjunction with natural ECM depo-
sition for the conservation of structural mechanical
properties and the prevention of aneurysmal dilation. AfterThe Journal of Thoracic and Ca>1 year, despite signs of degradation with macrophage in-
filtrate seen histologically, our biodegradable PCL grafts
showed no signs of aneurysmal dilations or mechanical
weaknesses. This is probably a result, in part, of the slow
degradation rate of PCL and of the collagen accumulation
in the graft body. Although it is difficult to know to what
proportion the ECM is contributing to the net mechanical
strength, we know that up to 18 months, our degrading graft
has sufficient strength to withstand arterial pressure.
After 1.5 years of implantation, local thickening of the in-
tima under the endothelium could be found in all PCL and
ePTFE grafts. Because the average thickness of this layer in
PCL is low and no flow obstruction can be observed, the
neointima present does not seem to be evolving toward
a pathologic condition. This is not necessarily true in therdiovascular Surgery c Volume 146, Number 2 405
FIGURE 4. Evaluation of calcium content. The microcomputed tomographic 3-dimensional images of the full grafts taken ex vivo immediately after ex-
plantation reveal calcifications in yellow and noncalcified tissues in dark brown. Some localized calcifications are found in PCL grafts (A) whereas ePTFE
grafts are subject to more extended calcifications (B), and no calcified tissues are detected in the control native aorta (C). PCL, Polycaprolactone; ePTFE,
expanded polytetrafluoroethylene.
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ness of neointima, potentially predisposing to further occlu-
sion, as found in this group of implants.
In terms of tissue regeneration, after 12 to 18 months, the
PCL graft bodies are populated mainly by macrophages, ad-
ventitial giant cells, and fibroblasts, some of which are
myofibroblasts. Moreover, limited neo-angiogenesis is de-
monstrable and is a favorable phenomenon compared
with ePTFE implants. With regard to the latter, neo-
angiogenesis is not as important because it is a stable graft,
but it becomes crucial for all biodegradable implants in
which tissue regeneration provides appropriate mechanical
resistance and what is sought—integration with the host.
Biomaterial-related calcification of cardiovascular im-
plants has been described previously17,18 and is not only
a rat-specific reaction, because it is detected in most clini-
cally implanted ePTFE grafts, even after short periods of
implantation, if it is sought.19 Biomaterial-related calcifica-
tion is also observed in our study in both the PCL and
ePTFE grafts. The microcomputed tomographic scans
show that total calcium content is significantly more impor-
tant in the ePTFE grafts than in the PCL grafts.
As demonstrated in this article, we can determine the
compliance in vivo by a very effective and noninvasive
method, opening up the possibility of following the compli-
ance of implanted grafts. In vitro compliance is inherent to
the material and the manufacturing process, and will change
after implantation as a result of degradation, tissue in-
growth, ECM formation, and calcification. Our results
show a difference in elasticity, indicating a compliance mis-
match for PCL grafts compared with the adjacent native
aorta. The main problem associated with compliance mis-
match is the development of intimal hyperplasia, which406 The Journal of Thoracic and Cardiovascular Surgcan lead to graft failure.20 The better patency of PCL im-
plants compared to ePTFE grafts could be explained in
part by improved vascular compliance that potentially
diminished unfavorable stimulus for intimal hyperplasia
formation
Study Limitations
This study is based on a limited number of animals be-
cause of ethical veterinary considerations (3R Rule) and
governmental regulations on the number of experimental
animals used. We kept our study follow-up survival up to
18 months, which represents almost a lifespan for a rat. Fur-
ther observation becomes very hazardous because of possi-
ble late appearance of malignancies and other diseases in
old rats. Abdominal aorta replacement in the rat is an estab-
lished model with a limitation of representing a high-flow/
high-shear rate situation despite the small size of our
implants. Obviously, different mechanical and rheologic
conditions are found in peripheral arterial vessels. There-
fore, a large-animal model such as porcine carotid artery re-
placement should be used as a preclinical pivotal study.
However, our model seems to be a simple and robust
method for graft testing in small animals. Furthermore, en-
hancement of graft compliance is an important issue to
reduce compliance mismatch between our prostheses and
a native artery.
CONCLUSIONS
Outcomes of synthetic, biodegradable, nanofiber, electro-
spun PCLgrafts are not inferior comparedwith the clinically
used stable ePTFE grafts after long-term implantation in the
rat aorta. Of the 8 PCL grafts evaluated, all were patent with
no signs of stenosis; had no aneurysmal dilation despiteery c August 2013
Mugnai et al Evolving Technology/Basic Sciencedegradation; were fully reendothelialized and thus resistant
to thrombosis; had limited, nonprogressing intimal hyper-
plasia; and hadmuch less calcification as well as better com-
pliance than ePTFE grafts. These grafts may, therefore, have
the potential to provide a better clinical outcome for small-
vessel revascularization procedures than ePTFE grafts.
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immunohistochemistry preparations, Marie-Claude Reymond for
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FIGUREE1. Evaluation of graft compliance. The inner diameter of poly-
caprolactone grafts and the adjacent abdominal aorta of a rat were mea-
sured in vivo from high-resolution ultrasound images during diastolic
(A) and systolic (B) phases. Concomitant noninvasive systolic and diastolic
blood pressures were recorded. AA, Aorta; L, length.
FIGURE E2. Results of in vivo compliance. The compliance of PCL im-
plants was significantly greater than ePTFE grafts (mid graft). The compli-
ance of both the PCL and ePTFE grafts were significantly less than adjacent
parts of native aortas (proximal and distal) and control (nonoperated in-
frarenal abdominal aortas). PCL, Polycaprolactone; ePTFE, expanded pol-
ytetrafluoroethylene.*,**,#,##,x P<.01.
FIGUREE3. Results of morphometric analysis. (A) The average neointima thickness of PCL implants was significantly less than in ePTFE grafts. (B) The
percent transmural cellular in-growth was greater in PCL than in ePTFE. PCL, Polycaprolactone; ePTFE, expanded polytetrafluoroethylene; SD, standard
deviation.
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